{"id":710162,"date":"2024-08-15T17:12:01","date_gmt":"2024-08-15T17:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=710162"},"modified":"2024-08-15T17:12:01","modified_gmt":"2024-08-15T17:12:01","slug":"adenoid-cystic-carcinoma-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-hlb-ayala-pharma-merck-amgen-curevac-actuate-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adenoid-cystic-carcinoma-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-hlb-ayala-pharma-merck-amgen-curevac-actuate-therapeutics_710162.html","title":{"rendered":"Adenoid Cystic Carcinoma Market to Grow at a Substantial Growth Rate During the Forecast Period | HLB, Ayala Pharma, Merck, Amgen, CureVac, Actuate Therapeutics"},"content":{"rendered":"
\n
\"Adenoid<\/a><\/div>\n
\n
Adenoid Cystic Carcinoma Market<\/div>\n<\/div>\n<\/div>\n
According to DelveInsight, the dynamics of the Adenoid Cystic Carcinoma market are expected to evolve in the coming years due to the anticipated introduction of new therapies, increased awareness of the disease, and advancements in research and development by leading biotech companies.<\/div>\n

The emerging pipeline for the treatment of Adenoid Cystic Carcinoma is robust. Pharmaceutical companies like Merck, Ayala Pharmaceuticals, etc., are investigating many combination products in this disease area.<\/p>\n

DelveInsight’s “Adenoid Cystic Carcinoma (ACC) Market Insights, Epidemiology, and Market Forecast 2032<\/a>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adenoid Cystic Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Adenoid Cystic Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n

Adenoid Cystic Carcinoma Overview<\/p>\n

Adenoid cystic carcinoma (ACC) is a rare type of adenocarcinoma that originates in glandular tissue. It most commonly develops in the salivary glands or other areas of the head and neck, but it can also appear in other body parts. ACC tumors are distinguished by a unique histological pattern of abnormal “nests” or cords of epithelial cells that surround or invade ducts or glandular structures within the affected organ. These structures often contain mucous-like material or abnormal fibrous membranes, which are visible under microscopic examination.<\/p>\n

ACC is considered a low-grade malignancy with slow growth. While it is rarely invasive and generally does not affect nearby lymph nodes or perineural spaces, it tends to recur locally. Approximately half of the patients experience metastasis to distant sites, especially the lungs, leading to potentially life-threatening complications. Unlike many other carcinomas, most ACC patients survive for at least 5 years, although tumors often recur and progress after this period.<\/p>\n

Adenoid Cystic Carcinoma Market Key Facts<\/a><\/p>\n

According to Calderón Boyle et al. (2020), in the US, the Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75–79 years and in females and lowest among Native Americans\/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.<\/p>\n

According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively, with treatment failure in 46% cases while distant failures in 34%.<\/p>\n

Several major pharma and biotech companies are working in the Adenoid Cystic Carcinoma Market, such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co, and others.<\/p>\n

Adenoid Cystic Carcinoma Market<\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Adenoid Cystic Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n

The report gives complete detail of the Adenoid Cystic Carcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n

Adenoid Cystic Carcinoma Epidemiology Assessment<\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.<\/p>\n

The Report Covers the Adenoid Cystic Carcinoma Epidemiology, Segmented as –<\/p>\n

Total Incidence Cases of ACC in the 7MM [2019–2032]<\/p>\n

Gender-specific Incidence cases of ACC in the 7MM [2019–2032]<\/p>\n

Grade-specific Incidence cases of ACC in the 7MM [2019-2032]<\/p>\n

Treatable cases of ACC in the 7MM [2019-2032]<\/p>\n

Adenoid Cystic Carcinoma Drugs Uptake and Pipeline Development Activities<\/p>\n

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Adenoid Cystic Carcinoma market or expected to be launched during the study period. The analysis covers the Adenoid Cystic Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Adenoid Cystic Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Learn How the Adenoid Cystic Carcinoma Market Will Evolve and Grow by 2032 @ https:\/\/www.delveinsight.com\/sample-request\/adenoid-cystic-carcinoma-acc-market<\/a><\/p>\n

Adenoid Cystic Carcinoma Therapeutics Analysis<\/p>\n

Several major pharma and biotech giants are developing therapies for Adenoid Cystic Carcinoma. Ayala Pharmaceuticals is leading the therapeutics market with its Adenoid Cystic Carcinoma drug candidates in the most advanced stage of clinical development.<\/p>\n

Leading Companies in the Adenoid Cystic Carcinoma Therapeutics Market Include:<\/p>\n

Ayala Pharmaceuticals<\/p>\n

CureVac<\/p>\n

Elevar Therapeutics<\/p>\n

Actuate Therapeutics<\/p>\n

Merck & Co.<\/p>\n

SHEPHERD Therapeutics<\/p>\n

Actuate Therapeutics<\/p>\n

Amgen<\/p>\n

And Many Others<\/p>\n

Adenoid Cystic Carcinoma Emerging and Marketed Drugs Covered in the Report Include:<\/p>\n

Rivoceranib : HLB<\/p>\n

Lenvatinib and Pembrolizumab: Merck<\/p>\n

AL101: Ayala Pharmaceuticals<\/p>\n

AMG 232 : Amgen<\/p>\n

CV8102: CureVac AG<\/p>\n

Elraglusib: Actuate Therapeutics<\/p>\n

And Many More<\/p>\n

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https:\/\/www.delveinsight.com\/sample-request\/adenoid-cystic-carcinoma-acc-market<\/a><\/p>\n

Table of Contents<\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary<\/p>\n

3. Adenoid Cystic Carcinoma Competitive Intelligence Analysis<\/p>\n

4. Adenoid Cystic Carcinoma Market Overview at a Glance<\/p>\n

5. Adenoid Cystic Carcinoma Disease Background and Overview<\/p>\n

6. Adenoid Cystic Carcinoma Patient Journey<\/p>\n

7. Adenoid Cystic Carcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)<\/p>\n

8. Adenoid Cystic Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Adenoid Cystic Carcinoma Unmet Needs<\/p>\n

10. Key Endpoints of Adenoid Cystic Carcinoma Treatment<\/p>\n

11. Adenoid Cystic Carcinoma Marketed Products<\/p>\n

12. Adenoid Cystic Carcinoma Emerging Drugs and Latest Therapeutic Advances<\/p>\n

13. Adenoid Cystic Carcinoma Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Adenoid Cystic Carcinoma Market Outlook (In US, EU5, and Japan)<\/p>\n

16. Adenoid Cystic Carcinoma Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Adenoid Cystic Carcinoma Market<\/p>\n

18. Adenoid Cystic Carcinoma Market Drivers<\/p>\n

19. Adenoid Cystic Carcinoma Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

Download a free sample report @ https:\/\/www.delveinsight.com\/sample-request\/adenoid-cystic-carcinoma-acc-market<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Adenoid Cystic Carcinoma Market According to DelveInsight, the dynamics of the Adenoid Cystic Carcinoma market are expected to evolve in the coming years due to the anticipated introduction of new therapies, increased awareness of the disease, and advancements in research … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-710162","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/710162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=710162"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/710162\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=710162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=710162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=710162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}